Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101976 | 0.92 | GCGR (0.44) | GCGRRAB9ANPC1MAPTLMNA | |
| SCHEMBL4092096 | 0.86 | GCGR (0.67) | GCGRRAB9ANPC1MAPTKMT2A | |
| SCHEMBL6751922 | 0.85 | EPHX2 (0.42) | GCGRMAPTLMNASMN1; SMN2EPHX2 | |
| SCHEMBL4081733 | 0.84 | EPHX2 (0.45) | GCGREPHX2CYP2D6 | |
| SCHEMBL2651702 | 0.84 | GCG (0.43) | GCGRRAB9ANPC1MAPTLMNA | |
| SCHEMBL2651718 | 0.84 | GCGR (0.50) | GCGRRAB9ANPC1MAPTLMNA | |
| SCHEMBL2651057 | 0.83 | GCGR (0.46) | GCGRRAB9ANPC1MAPTLMNA | |
| SCHEMBL2653146 | 0.82 | GCGR (0.50) | GCGRNPC1MAPTKMT2AMEN1 | |
| SCHEMBL6754090 | 0.81 | EPHX2 (0.45) | GCGRNPC1MAPTLMNAKMT2A | |
| SCHEMBL2650215 | 0.81 | GCGR (0.76) | GCGRRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | MADSEN PETER (DK) | 2004-07-01 | — | — | US | claimed |
| US-6706744-B2 | HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS | NOVO NORDISK A/S (DK) | 2004-03-16 | — | — | US | claimed |
| WO-2002040444-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127560-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | GCGR 3/4885RAB9A 2872/4885NPC1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.